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This article reviews efforts in accurate experimental charge-density studies with
relevance to medicinal chemistry. Initially, classical charge-density studies that
measure electron density distribution via least-squares refinement of aspherical-
atom population parameters are summarized. Next, interaction density is
discussed as an idealized situation resembling drug–receptor interactions.
Scattering-factor databases play an increasing role in charge-density research,
and they can be applied both to small-molecule and macromolecular structures
in refinement and analysis; software development facilitates their use. Therefore
combining both of these complementary branches of X-ray crystallography is
recommended, and examples are given where such a combination already
proved useful. On the side of the experiment, new pixel detectors are allowing
rapid measurements, thereby enabling both high-throughput small-molecule
studies and macromolecular structure determination to higher resolutions.
Currently, the most ambitious studies compute intermolecular interaction
energies of drug–receptor complexes, and it is recommended that future studies
benefit from recent method developments. Selected new developments in
theoretical charge-density studies are discussed with emphasis on its symbiotic
relation to crystallography.
1. Abbreviations
ADPs: anisotropic displacement parameters
CD: charge density
DI: delocalization index
EDD: electron density distribution
EDWCM: electron-density-weighted connectivity matrix
ELMAM2: experimental library multipolar-atom model
EP/MM: exact potential and multipole methods
ESP: electrostatic potential
GID: generalized invariom database
IAM: independent-atom model
KEM: kernel energy method
LDM: localization–delocalization matrix
LI: localization index
QTAIM: quantum theory of atoms in molecules
SBFA: supramolecular synthon-based fragments approach
TLS: translation, libration and screw motion
UBDB: University at Buffalo Databank
XRD: X-ray diffraction
2. Introduction
Research challenges in biomedical and medical research are
fascinating and intrigue many researchers. In how far small-
molecule (Wouters & Ooms, 2001) and macromolecular
(Anderson, 2003) XRD can contribute to processes such as
drug design and development is the subject of intensive
research (Davis et al., 2003). Contributions to and success
stories of structure-based drug design were also discussed in
a textbook (Klebe, 2009). The focus of this article is
experimental CD research, historically the specialized area
of small-molecule X-ray crystallography that focuses on
high accuracy, and its relevance to medicinal chemistry. Since
a comprehensive review article covering biophysical and
biological properties derived from theoretical CD has been
published very recently (Matta, 2014), only experimental
CD and some selected aspects of theoretical CD research
will be covered here. For an introduction to general CD
research, the monographs by Tsirelson & Ozerov (1996) and
Coppens (1997), and the review articles by Spackman &
Brown (1994), Spackman (1998), Koritsánszky & Coppens
(2001) and Stalke (2011) are recommended. The essence of
experimental CD work is that one measures (r), the EDD
of a molecule in the solid state, more specifically a molecule
surrounded by countless other molecules in a close packing
arrangement — unlike in quantum chemistry, where usually
only the EDD of a molecule in the gas phase is considered.
Experimental CD research commenced with an X—N
difference electron density study on s-triazine (Coppens,
1967). For the first time, it allowed visualization of the rear-
rangements of (r) due to chemical bonding, which was
predicted to be possible by Debye (1915). CD research quickly
developed to be one of the research areas at the forefront of
method development in XRD, pushing this branch of science
forward in the 1970s to the 1990s. The coming of age of clas-
sical CD studies, where multipole population parameters of
aspherical scattering factors are adjusted to high-resolution
Bragg data by least-squares refinement, was declared a decade
ago (Coppens, 2005) and there is, in principle, no limit on the
size of the system studied.1 The tremendous drive and
progress in protein crystallography superseded the leading
role of CD in method development with completely opposite
problems to be solved, i.e. handling low-resolution rather than
ultrahigh-resolution (Jelsch et al., 2000) data. Nevertheless,
both areas are still advancing the capabilities of XRD in
opposite but complementary directions with respect to chal-
lenges in medicinal chemistry. The coming of age of low-
resolution protein crystallography has equally been declared
(Brünger, 2006) and developments in structural biology have
empowered structural biologists in their endeavors, which has
led, for example, to the award of the 2009 Nobel Prize in
Chemistry to Ada Yonath (Yonath, 2010), Thomas Steitz
(Steitz, 2010) and Venkatraman Ramakrishnan (Ramak-
rishnan, 2010) for elucidating the structure and function of the
ribosome.
3. Combining experimental CD and protein
crystallography
One topic of interest shared by CD studies and protein crys-
tallography is the experiment because both require the best
attainable data to give the most reliable answer to a particular
structural problem. Here both research areas, CD (Coppens et
al., 1974; Larsen, 1995; Stalke, 1998; Hardie et al., 1998) and
macromolecular crystallography (Hope, 1990; Garman, 1999;
Petrova et al., 2006; Chinte et al., 2007) usually rely on the use
of low-temperature data collection and synchrotron radiation
(Coppens, 1992; Helliwell, 1998); for example, when trying to
identify the protonation state of a residue (Dauter et al., 1997),
when collecting multiple anomalous dispersion data for
solving the phase problem (Dauter et al., 1998), or when data
devoid of strong bias from extinction and absorption of metal
containing coordination complexes are collected to the highest
possible resolution with hard X-rays (Schmökel et al., 2013).
Distinction between small-molecule and macromolecular
crystallography can appear such as a divide not unlike that
between neighboring branches of science, e.g. biology and
chemistry.2 This divide is counterproductive for advancing the
possible impact of CD research on medicinal chemistry, or to
tackle challenges in macromolecular crystallography that are
usually not encountered by small-molecule crystallographers;
both rest on the same experimental foundations, mathematical
background and underlying physical effects. On the contrary,
combining the expertise of both branches of crystallography is
fruitful to study research questions of medical relevance. One
example is the use of on-the-fly computation of three-
dimensional Fourier difference electron density maps in
macromolecular crystallography (Emsley & Cowtan, 2004),
and their subsequent implementation in small-molecule soft-
ware (Hübschle & Dittrich, 2011; Hübschle et al., 2011),
another avoiding different use of symbols and definitions for
atomic displacement parameters (Trueblood et al., 1996).
More recently, both small-molecule and macromolecular
crystallography are being applied together in research rele-
vant to medicinal chemistry (Dominiak et al., 2009; Malińska et
al., 2014), and it is these developments and challenges of such
applications that are both the focus and culmination of this
article. Such studies should ultimately rely on accurate struc-
tural knowledge of both receptor and drug molecules, and
therefore require the techniques and methodologies in both
research areas to be combined.
4. Developments of CD work – relevant to medicinal
chemistry?
The focus on high accuracy, by improving experimental
conditions, equipment and choice of specimen, can be seen as
both a blessing and a curse to experimental CD work. On one
hand, it is necessary to aim for the best possible experiment
(Seiler, 1992; Destro et al., 2004; Zhurov et al., 2008) using the
feature articles
458 Dittrich and Matta  Charge-density research and medicinal chemistry IUCrJ (2014). 1, 457–469
1 In practice, the increasing number of disordered atom sites with molecular
size is certainly a limit.
2 One can sometimes observe misunderstandings between small-molecule and
macromolecular crystallographers, maybe because either side might lack the
specific experiences of the other.
most sophisticated model to study a particular research
question. On the other hand, a methodology that requires the
best possible experimental result excludes studying many
interesting research questions of broader relevance where
experimental requirements (Blessing & Lecomte, 1991;
Koritsánszky et al., 1998) cannot be met. This was the starting
point for the development of scattering-factor databases
(Brock et al., 1991), initially to improve the accuracy of ADPs
(Jelsch et al., 1998; Dittrich et al., 2008), then to improve
structural least-squares refinement of oligopeptides (Pichon-
Pesme et al., 1995) and small proteins (Jelsch et al., 2000), and
ultimately light-atom structures in general (Dittrich et al.,
2004, 2013). A second, equally valid starting point was to
obtain properties3 and then intramolecular interaction ener-
gies from aspherical atoms (Li et al., 2002; Volkov, Li et al.,
2004; Jarzembska & Dominiak, 2012). Most recently such an
analysis was applied to macromolecular systems. We here
consider these methods, mostly developed in the last two
decades, to be part of the field of CD research, as the unifying
aim of high accuracy is shared, although their experimental
requirements are different to classical CD work: scattering-
factor libraries4 providing the EDD can be applied to data sets
of normal resolution in the refinement of positions and atomic
displacement parameters (speaking from the viewpoint of a
small-molecule crystallographer, i.e. data sets that fulfill the
requirements of the journal Acta Cryst. Section C: 25 in 2
with Mo K radiation, which is approximately sin = =
0.6 Å1 or d = 0.84 Å), as the multipole populations of the
scattering factors do not need to be refined anymore but are
used unchanged as tabulated. Hence, using a fixed scattering
factor of the pseudoatom model (Stewart, 1976) as modified
by Hansen & Coppens (1978) opens up the field to such
research problems, where the data resolution and quality
required are simply not currently measurable. Such approa-
ches therefore substantially increase the reach of CD research.
Property calculations using the EDD calculated from the
tabulated multipole parameters to obtain properties require
only a set of molecular coordinates, in principle also from data
of lower resolution or methods other than XRD. Whether
scattering-factor databases are also suitable for refinement in
protein crystallography, where atomic resolution is already
considered high, and whether coordinates from low-resolution
refinement are good enough for obtaining reasonable prop-
erties will be important questions that are discussed below. We
will first look at classical CD studies with relevance to
medicinal chemistry before we move on to such applications of
databases.
5. Classical CD research in medicinal chemistry
Classical CD studies of drug and macromolecular receptor are
impossible as long as truly ultrahigh-resolution data become
available for macromolecules and until the challenge of
treating disorder has been successfully tackled. Because such
ideal situations are unavailable, it is constructive to first study
separately a single, active small-molecule pharmaceutical
ingredient. Many such studies have been performed (Howard
et al., 1995; Flaig et al., 2001; Hibbs et al., 2003; Ghermani et al.,
2004; Destro et al., 2005; Soave et al., 2007; Rajalakshmi et al.,
2014), more recently also on a pair of polymorphs (Overgaard
& Hibbs, 2004; Nelyubina et al., 2010), a series of pharma-
ceutically active molecules (Zhurova et al., 2006; Parrish et al.,
2006; Yearley et al., 2007; Zhurova et al., 2009; Grabowsky et
al., 2008) and anion–receptor complexes (Kirby et al., 2014) in
comparative CD studies, to give just a few examples. For
further illustration a study on two penicillin molecules, one
active and one inactive (Wagner et al., 2004), will now be
discussed in slightly more detail. A question underlying this
and several other studies was whether the experimental EDD
would provide an indication on activity from bond topology
following Bader’s QTAIM (Bader, 1990). This turned out not
to be the case because the experimental topology was very
similar within the standard deviation (Dittrich et al., 2002) for
similar bonds in an active and a non-active penicillin deriva-
tive; similarity was defined as sharing the same chemical
environment. The ESP (Náray-Szabo & Ferenczy, 1995)
proved rather more useful (Stewart, 1979; Stewart & Craven,
1993). Encouragingly an agreement between theoretical and
experimental ESP, with the latter being slightly more
extended, could be established (Dittrich et al., 2000), and for
the active penicillin the ESP confirmed the established
mechanism of action. Many subsequent studies of the ESP
applied an analysis introduced by Politzer et al. (2001) in order
to be able to identify and quantify characteristics of particular
classes of compounds. Still, classical CD studies can be time-
consuming, require a non-disordered structure and high
crystal quality. Often only a few out of a series of compounds
fulfill these specific requirements. A subsequent contribution
to this research area relied on the invariom database, bene-
fitting from already measured conventional data. This allowed
12 X-ray data sets of nine active fluoroquinolones to be
studied in a reasonably short time using published, remea-
sured and newly determined structures with different crystal
quality (Holstein et al., 2012). Although not strictly an
experimental CD study anymore because the EDD is taken
from the database, having a larger sample of molecules at
hand that were treated in a consistent manner provided more
insight: active molecules sharing the same mechanism of
action did also show a very similar ESP for the same proto-
nation state. The ESP derived from several scattering-factor
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3 Dipole moments and higher multipole moments (Spackman et al., 2007), the
molecular ESP, bond topological properties according to Bader’s quantum
theory of atoms in molecules (QTAIM; Bader, 1990) and other descriptors
(Gatti, 2005), the electric field gradient, electronic energy distributions
(Tsirelson, 2002) and (in combination with other assumptions) intermolecular
interaction energies can be obtained from experimental EDD.
4 There are currently four scattering-factor databases: the supramolecular
synthon-based fragments approach (SBFA; Hathwar et al., 2011), the
generalized invariom database (GID; Dittrich et al., 2006, 2013), the
University at Buffalo Databank (UBDB; Dominiak et al., 2007; Jarzembska
& Dominiak, 2012) and the experimental library multipolar-atom model
(ELMAM2; Zarychta et al., 2007; Domagała et al., 2012). While SBFA and
ELMAM2 are based on refinement of multipoles from experimental high-
resolution diffraction data, GID and UBDB scattering factors are derived
from DFT computations; GID from optimized structures of model compounds
and UBDB from single-point energy computations of selected crystal
structures.
databases has recently been compared and was found to agree
well between all of them (Bąk et al., 2011). It can be consid-
ered that such methodology is established and reliable for
studies on small molecules. However, to understand biological
processes in full detail both the accurate EDD of small
molecule drug and macromolecular receptors are required,
and dynamic processes also need to be taken into considera-
tion.
An important aspect with respect to ESPs and other
properties derived from classical CD studies is undetected
disorder because multipole parameters correlate with the site
occupancy of an atom in question, thereby invalidating the
EDD of a disordered atom and influencing its environment. It
has been shown that properties such as the ESP derived from
an EDD where rotational or other subtle disorder has not
been spotted become unreliable or in error (Dittrich, Warren
et al., 2009; Bąk et al., 2009). Here the solution to arrive at the
correct result is reverting to theory and to rely on database
parameters for populations of those atoms affected (Holstein
et al., 2010).5 The example of 2-methyl-4-nitro-1-phenyl-1H-
imidazole-5-carbonitrile shows how easy it is to overlook, for
example, rotational disorder of a methyl group (Poulain-Paul
et al., 2012).
An analysis with an experimental-minus-invariom differ-
ence density (Dittrich et al., 2007) using the authors’ deposited
data clearly shows disorder to be present (Fig. 1). This matters
because rotational disorder can also bias the experimental
dipole moment, and this might explain some of the differences
observed between experiment and theory.
In summary, the investigations cited in this section and
many other studies of this kind show that experimental CD
work does provide valuable information on molecules in the
crystal and their properties, but the effort involved is often
considerable. The outlook is positive though, and we can
expect the time of both modeling process and experiment to
be further reduced in the future (Hübschle et al., 2007;
Schürmann et al., 2012) as previously anticipated (Luger,
2007).
6. Interaction density – relevant fundamental research
Interaction density6 is relevant to medicinal chemistry because
crystallization is a molecular recognition process. Crystal-
lization (and interaction density) can be seen as an idealized
situation that is analogous to drug–receptor interactions and
the redistribution of electron density of a drug molecule in the
active site. Hence, it would be of considerable interest to
understand whether or not the process of a molecule
becoming polarized helps crystallization, or is just a conse-
quence of it. What one could learn from answering this
question would be directly relevant to other molecular
recognition processes, here, for example, drug–receptor
interactions.
The starting point in studying interaction density from a CD
point of view was Bader’s QTAIM and difference electron
density studies to understand and visualize the redistribution
of (r) of a hypothetical molecule in the gas phase and one
that is part of the crystal environment (Gatti et al., 1994;
Spackman et al., 1999). Unfortunately, further studies
(Dittrich & Spackman, 2007) were complicated by technical
problems, for example, the limited flexibility of the single-zeta
Hansen–Coppens multipole model (Volkov & Coppens, 2001)
using parameters up to hexadecapoles. Here a basis-set
description, as available in the program Tonto (Jayatilaka &
Grimwood, 2003), has advantages in reproducing fine features
of the EDD (Dittrich et al., 2012). However, the measurement
of a lot more reflections than is currently possible would be
required for an experimental CD study employing even more
parameters. Although Hansen and Coppens have optimized
their model to describe covalent bonding of light-atom
structures, further advances in this area will continue to
require a considerable amount of work to explain differences
that become increasingly small.
The conclusion of studies of interaction density was that the
crystal field can indeed cause detectable redistributions of the
EDD in a molecule that is part of a crystal when compared
with its gas-phase counterpart with identical structure and
conformation. However, these differences are certainly small
(in the range of 0.25 e Å3), and just at the level where even
good data sets become noisy and the phases of noncen-
trosymmetric structure (Spackman & Byrom, 1997) become
affected by experimental errors (Souhassou et al., 1991). While
we still think that a qualitative experimental measurement is
indeed feasible with low-temperature data because studies
with model data (not taking into account thermal motion)
predicted that measurements should be possible, other
authors have been more skeptical (de Vries et al., 2000). In a
next step, energetic contributions of the electron density
feature articles
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Figure 1
If undetected, rotational disorder can lead to erroneous properties
derived from experimental CD studies. Useful for detecting it are
experiment-minus-invariom difference densities such as the one shown
above for 2-methyl-4-nitro-1-phenyl-1H-imidazole-5-carbonitrile. Green
(positive) and red (negative) iso-surface meshes of the Fourier difference
EDD at 0.1 e Å3.
5 One has to be aware that such studies are not really experimental CD studies
anymore.
6 The interaction density is the difference between the molecular EDD in the
crystal and a superposition of non-interacting molecules.
redistribution could be estimated, something we think is a
worthwhile endeavor. For now, it remains unclear how
important interaction density is for crystallization, and like-
wise how important electron density redistribution is for drug–
receptor interactions.
7. Current challenges in high-resolution
macromolecular crystallography
There are many interesting directions for method develop-
ment in macromolecular crystallography and these have
already been discussed elsewhere (Adams et al., 2013). One of
the most pertinent problems in macromolecular crystal-
lography with respect to CD work is the challenge of accuracy,
which is directly related to data resolution. Whereas almost all
protein structures are determined at resolutions above 0.5 Å,
classical CD methodology cannot be applied for studying such
structures. Our experience shows that even macromolecular
data sets that formally fulfill the requirements of CD research
(Blessing & Lecomte, 1991), or those getting close to fulfilling
these requirements, are usually unsuited owing to the
numerous disordered atoms, and there is currently only one
such example of the small protein crambin (Schmidt et al.,
2011) where a resolution below 0.5 Å has been reached.7
Despite several review articles that painted the future to be
bright (Schmidt & Lamzin, 2002; Vrielink & Sampson, 2003;
Petrova & Podjarny, 2004), achieving resolutions in macro-
molecular crystallography such as those that are routinely
reached in small-molecule crystallography more frequently
would be highly desirable.
Another way to improve the accuracy of macromolecular
structures, while not relying on experimental improvements, is
to use a more sophisticated scattering factor model beyond the
IAM usually used for refinement and subsequent analysis.
When using fixed aspherical scattering factors resolution
requirements as they apply in CD research can be reduced to a
certain degree (d = 0.84 Å) (Dittrich, Hübschle et al., 2009),
but a better model only makes physical sense for macro-
molecules when features of valence EDD can be observed
(Afonine et al., 2004). Although there are no additional
parameters being added with fixed aspherical scattering
factors (unlike in classical CD refinement), this approach
should at least not make the fit to the experimental Bragg
intensities worse even when this requirement is not entirely
met (Housset et al., 2000), and it has been shown to lead to
significant improvements in some systems (Guillot et al., 2008;
Dittrich et al., 2010; Pröpper et al., 2013) similar to what is seen
in small-molecule structures. There is currently only one
program designed (and suitable) for such refinements, because
it is, for example, capable of using restraints and has also
implemented the Hansen–Coppens multipole model, and that
is the program Mopro (Guillot et al., 2001; Jelsch et al., 2005).
An alternative model to improve macromolecular struc-
tures at ultrahigh resolution is based on the IAM, but addi-
tional parameters are required in the form of spherical
scatterers for bonding and lone-pair electron density (Hellner,
1977). This approach already had some utility (Afonine et al.,
2007) and one strong point is the ease of program imple-
mentation; an interesting recent study added atomic charges
to interatomic scatterers (Nassour et al., 2014). An alternative
way to improve macromolecular structures is the combination
of force-field calculations with structure refinement as in the
program CNS (Brünger et al., 1998), and to improve the force-
field description further by including polarization. This has
recently been shown to be possible (Schnieders et al., 2009).
Ultimately, the contribution of the experiment remains the
most important one, and the above-mentioned methods and
programming improvements only work and show their utility
most convincingly with the best current macromolecular data
sets.
Currently, the only possibility to solve the challenge of
positional inaccuracy and disorder with lower resolution data
is to include chemical knowledge in the form of restraints, or
to use constraints, for example, in the form of fixed aspherical
scattering factors. Restraints (Engh & Huber, 1991) have been
used in macromolecular crystallography for decades, since
classical least-squares refinement does not always provide a
physically correct answer, most obviously when a side chain is
dynamically disordered or when there are too many or highly
correlated least-squares parameters. Although the use of
restraints is well established in low-resolution protein refine-
ment, it is counterintuitive for small-molecule crystal-
lographers used to high resolution, and is conceptually hard to
swallow, especially for those who follow the ideal of measuring
experimental CD, where accurate measurements are the
center of interest.
It could be misconstrued that for truly high resolution,
protein data restraints are not required because the large
number of reflections leads to favorable overdetermination
for least-squares refinement. This is a misconception because
macromolecules almost always contain a substantial part of
dynamically disordered solvent and side chains. When such
disorder is present restraints are needed for protein data at
truly high resolution. On the other hand, the well behaving
parts of such a macromolecule would not need restraints at all
and permit free parameter adjustment. However, refined
distances might then disagree with the conventional Engh–
Huber restraints that were derived from the IAM that has
been shown to lead to inaccurate positional parameters
(Coppens et al., 1969). Therefore, these widely used restraints
are outdated when used in combination with aspherical scat-
tering factors. It would hence be highly desirable to have a
new set of bond-distance, bond-angle and other restraints
(Thorn et al., 2012) available (Jaskolski et al., 2007) that agree
both with neutron diffraction refinements (Gruene et al.,
2014), with theoretical computations and therefore also with
refinement results from incorporating aspherical scattering
factors. Structures refined with newly developed restraints for
use with aspherical scattering factors should then also give
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7 Here the next problem to be addressed might be radiation damage (Holton,
2009).
more accurate results in subsequent analysis of their inter-
molecular interaction energies (see below). Last but not least,
another important point is that new restraints are required not
only for the constituting chemical environments of the protein
or DNA macromolecules, but also for solvent molecules, all
possible ligands or other (small molecule) cofactors (Kley-
wegt, 2007).
Another challenge is the treatment of hydrogen atoms,
which has been the subject of continuous studies over the
decades (Stewart et al., 1965). Hydrogen atoms have a weak
scattering contribution, mainly in the low-order region of the
diffraction pattern, and the accurate determination of their
positional and displacement parameters is therefore a funda-
mental problem of single-crystal XRD (Engler et al., 2003;
Munshi et al., 2008; Jayatilaka & Dittrich, 2008; Hoser et al.,
2009). Historically, neutron diffraction data have often been
collected in parallel to collecting small-molecule high-resolu-
tion XRD data. However, such studies have been infrequent
because requirements on crystal volume have historically been
difficult to fulfill. Despite improvements in technology, their
number has not increased because the number of machines
available for such experiments continues to be limited. Hence
until today, when analogous studies are being applied in
macromolecular crystallography (Afonine et al., 2010), such
experiments are not being carried out as often as they should
be.
The most noteworthy development in small-molecule
crystallography, in this context, is the combination of X-ray
and neutron scattering experiments and analysis to give spin-
resolved electron distributions (Deutsch et al., 2014). Never-
theless, improvements in the hydrogen-atom treatment remain
possible without invoking neutron diffraction and it has
recently been shown that even the standard riding hydrogen
treatment can be improved (Lübben et al., 2014); we plan to
continue this work by estimation of ADPs, following up on
earlier work by Madsen (2006) and Whitten & Spackman
(2006). Frequency computations of the model compounds in
the invariom database will be combined with a TLS fit for that
purpose, thereby avoiding additional least-squares parameters
for refinement of hydrogen atoms.
A recurring theme in this article is accuracy; further
improving the experimental data quality of macromolecules
will continue to be helpful and important. Modern detectors
(Broennimann et al., 2006; Toyokawa et al., 2010) certainly
help in achieving this goal. However, the study of small
molecules, where crystals remain stable and do not show much
radiation damage during the course of measurement, can
certainly help us to understand how to improve data quality
with new equipment. Low-order data are especially relevant
for macromolecular structure determination in the presence of
a disordered solvent and for observing deformation EDD, and
we frequently observe problems with pixel detectors. The
article by Dauter (2003) showed how high-quality low-order
data for macromolecular structures can be collected with CCD
detectors. Such a study remains to be repeated for the new
generation of pixel detectors that are replacing CCD detectors
at synchrotrons.
8. Opportunities and challenges of combined CD and
macromolecular work in medicinal chemistry
A long term aim in CD research has been to extract physical
properties, such as, for example, the interaction energy, from
the experimental EDD in the solid state. This research has had
a long history and a readable introduction to it has recently
been provided as a book chapter (Dominiak et al., 2012) where
the different approaches are comprehensively covered and
compared, while also giving account of existing literature. The
computation of the interaction energy (or the electrostatic
contribution to the interaction energy) from experimental or
database electron density may be the most ambitious but also
the most promising goal in combining CD and macro-
molecular crystallography. Analogous to the interaction
density that is smaller than the bonding and core electron
density, the interaction energy is orders of magnitude smaller
than the energy of the molecules themselves. Another simi-
larity is that the interaction energy is a feature of the crystal
packing, and is an energy difference. Many studies have been
carried out to obtain interaction energies in small-molecule
systems (Spackman & Weber, 1988; Abramov et al., 2000a,b; Li
et al., 2002; Soave et al., 2007; Bouhmaida et al., 2009). These
pivotal studies provided very useful experiences, including an
assessment of accuracy and the EP/MM approach (Volkov,
Koritsánszky & Coppens, 2004) currently seems closest to a
user-friendly implementation of the concepts involved. Being
able to carry out high-throughput studies of a series of related
drug compounds with different affinity for quantitative prop-
erty screening is certainly a future requirement on the side of
small-molecule crystallography. Another interesting new
development is to also assess weak intermolecular interactions
from database electron density (Nelyubina et al., 2014).
Much progress has also been made concerning interaction
energies of macromolecular drug–receptor complexes from
databases. Parameters describing the electron density of both
the building blocks for proteins (Domagała et al., 2012) and
DNA (Jarzembska & Dominiak, 2012) and many other
possible chemical environments (Dittrich et al., 2013) are
available in the above-mentioned scattering factor databases,
and the stage is set for studying drug–receptor interactions
quantitatively. The most eye-catching current studies in the
area have been on neuraminidase (Dominiak et al., 2009) and
sunitinib in complexes with different kinase receptors
(Malińska et al., 2014) using the UBDB (Jarzembska &
Dominiak, 2012), which was designed to reproduce as well as
possible the theoretical interaction energies with the Hansen–
Coppens multipole model, whereas the aim in developing the
invariom database was to provide better structures. Both aims
are closely related, because only with good positional para-
meters and deconvoluted ADPs can accurate properties be
obtained. Hence, protein structures of limited resolution can
be suspected not to be a very good starting point for providing
accurate interaction energies. This is why we advocate for
continuous improvements in high-resolution protein refine-
ment, for example, by testing re-refinement with deposited
data, or better, with newly measured X-ray data to the best
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possible resolution. The work on aldose reductase (Guillot et
al., 2008) is pioneering especially in this respect, because for
the first time a real enzyme with hundreds of amino acids was
studied at a very respectable resolution, even together with an
inhibitor, and aspherical-atom refinements were carried out
on the system. Suspected (Lichtenthaler, 1994) electrostatic
complementarity (Muzet et al., 2003) has been confirmed and
will remain to be a very useful concept. We share the aim of
using aspherical scattering factors in refinement, and have
carried out two related studies on the two peptide antibiotics
trichotoxin A50E (Dittrich et al., 2010) and thiostrepton
(Pröpper et al., 2013) with the XD suite of programs (Volkov et
al., 2006), systems that are however an order of magnitude
smaller than aldose reductase. Another aspect regarding the
calculation of interaction energies is that the Hansen–
Coppens density model may, without modification, not be
sophisticated enough to produce energies with a good degree
of accuracy (Bąk et al., 2011). Nevertheless, despite the chal-
lenges encountered, work on aldose reductase, trichotoxin
A50E, neuraminidase, thiostrepton and sunitinib are currently
the best efforts that can be made and guide the way.
9. Complementarity and synergy of experiment and
theory
Nowadays, it is common practice to support experimental
determinations of geometries and electron densities with
theoretical calculations both in the isolated molecular vacuum
phase and in the crystalline phase. This is so because the object
of the study, (r), is accessible from both ends: theory –
through the calculation of the many-electron wavefunction
ðx1; x2; :::; xNÞ, where xi are the space and spin coordinates
of the ith electron, and experiment – as discussed above from
the resolution of the crystallographic phase problem and
subsequent modeling of the resulting electron density.
The EDD, the ESP, the geometries, and all ground- and
excited-state properties are all uniquely mapped to one
another as has recently been emphasized (Matta, 2014) owing
to the operation of the Hohenberg–Kohn theorem (Hohen-
berg & Kohn, 1964). Structures, EDD and ESP are all three
accessible from both theory and state-of-the-art experiment
and with comparable precisions leading to a very desirable
synergy of theory and experiment. Theory can supply addi-
tional molecular descriptors obtained from the full density
matrix (normally accessible only from calculations) rather
than just the diagonal elements of this matrix that can be fitted
to experimental scattering data. In the remainder of this short
review, we select a few examples of the synergy and comple-
mentarity of quantum chemical theory and X-ray crystal-
lographic experiment for the sake of illustration rather than to
provide an exhaustive review.
Ab initio methods scale rapidly with the size of the system,
and as a result they often cannot be applied to very large
biological molecules of importance to medicinal chemistry. A
fragmentation solution to this problem, based on Bader’s
QTAIM, has been proposed and demonstrated to reproduce
the ab initio results at a fraction of the computational costs
using a series of morphine analogs (opioids) (Matta, 2001).
This method is termed the ‘buffered fragments approach’
because the properties of the large system are obtained from
calculations on small fragments embedded in an appropriate
(buffer) electronic environment similar to the environment in
the target molecule. The fragments are extracted from their
environments at their zero-flux surfaces (Bader, 2001) and
then combined to reconstruct the properties of the target
molecule. Such atomic partitioning of the electron density has
also been applied to EDD from single-crystal XRD and the
submolecular transferability that was previously demonstrated
on the basis of theoretical calculations (Matta, 2001) has
likewise been demonstrated for molecules of the same opioid
family based on experimentally determined EDD. Scheins et
al. (2005) have shown how to reconstruct an approximation to
the experimentally derived EDD of morphine from buffered
experimental fragments (Scheins et al., 2005) in concordance
with the theoretical counterparts. The goal of Luger et al.
extends beyond the particular chosen (opioids) systems to a
much broader proof of principle that the buffer fragments
methods can be used to obtain the EDDs of large molecules of
biological significance, an important contribution in efforts to
circumvent the experimental inaccessibility of the electron
densities of numerous large molecules of extreme biological
and pharmacological importance. It is noted in passing that the
buffered fragments reconstruction applies to both scalar and
vector properties. Examples of the former include molecular
volumes, and atomic and group charges (Matta, 2001; Scheins
et al., 2005), and examples of the latter include the dipole
moment or dielectric polarization (Bader, 2002; Bader &
Matta, 2001).
Another approach, developed by Huang, Massa and Karle,
is termed the kernel energy method (KEM) and it represents
another area of synergy between crystallography and ab initio
quantum mechanics. In this approach, X-ray crystallography
supplies the experimental coordinates and theory supplies the
fast and accurate estimate of the total energies, interaction
energies, stacking energies and binding energies. This ener-
getic dimension that is obtained from the quantum calcula-
tions using the experimental geometries is invaluable in the
modeling of large biomolecules, especially with regards to
host–guest, enzyme–substrate or enzyme–inhibitor interac-
tions (Huang et al., 2005a,b,c, 2006, 2009, 2010, 2011, 2014;
Massa et al., 1995). In this method, the energy of the full
system is obtained at chemical accuracy through a fragmen-
tation scheme which is different from that described above in
the buffered fragments method. The reason for the difference
is that when energies at an experimentally determined frozen
geometry are the prime sought for quantity, QTAIM cannot be
used because QTAIM energies in this case will include origin-
dependent contributions from the virials of the net non-
vanishing forces on the nuclei. The KEM provides a fast and
extremely accurate alternative that has been extensively tested
in the past decade (Huang et al., 2010). KEM partitions the
large molecule into double kernels, i.e. fragments capped with
hydrogen atoms, and which account for two-body interactions
between different regions of the molecule, corrected by the
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subtraction of the contributions of single kernels to remove
the over-counting of energies from the summations of the











where EKEM is the KEM energy of the full system, Eij is the
energy of the ijth double kernel, Ek is the energy of the kth
single kernel and n is the number of single kernels. Fig. 2
shows a comparison of the scaling of the CPU time for the
direct calculations and the corresponding scaling from KEM
calculations on the same species for a series of polypeptides.
The plots in Fig. 2 show the considerable computational
advantage of KEM over direct calculations particularly that
differences between KEM and exact energies are typically
below 1 kcal mol1 for molecules with several thousands of
atoms (Huang et al., 2011).
Recently, an important generalization KEM (Huang et al.,
2005a,b,c, 2006, 2009, 2010, 2014; Massa et al., 1995) has been
achieved, extending its domain of applicability well beyond
the calculation of energies (Huang et al., 2014). Indeed, KEM
has been shown to be remarkably capable of the accurate
prediction of response properties induced by external fields as
demonstrated by the stringent test of reproducing field-
induced changes in a highly delocalized finite system such as
graphene. The studied properties include the change in the
energy (E) and the change in the dipole-moment compo-
nents (i, i = x, y, z) of a large, finite hydrogen-terminated
graphene flake with errors practically zero for all studied
response properties and all field strengths and directions
(Huang et al., 2014). These results enable nonperiodic
quantum mechanical (cluster) calculations on extremely large
systems of biological and of nanotechnological interest;
impossible to achieve with existing computational technolo-
gies. Although the dipole moment is the second and a lead
term in an infinite expansion, it can be anticipated that the
total electron density scalar field itself can be obtained from
fragments according to an equation similar in form to the










where KEM is the approximate KEM electron density of the
full molecule to be reconstructed, ij and k are the electron
densities of the ijth double kernel and of the kth single kernel,
respectively, and r is a position vector (Huang et al., 2014).
Given an approximation to the density as in equation (2), all
one-electron properties represented by multiplicative opera-
tors can be calculated in addition to several derived properties
such as those obtained from Bader’s QTAIM.
The second example of synergy between XRD experiment
and theory is that which resulted in a simple mechanism for
peptide bond formation in the ribosome (Gindulyte et al.,
2006; Massa et al., 2010). Accurately determined atomic
positions of the 50 most important atoms at the ribosome
active site, obtained from Professor Yonath’s group, were used
as the input geometry for a computational EDD investigation
of the sequence of bond making and breaking in the ribosome.
The sequence of steps that lead to the formation of the peptide
bond in the active site of the ribosome has remained a subject
of debate and disagreement. A simple mechanism has been
proposed as a result of a study in which the evolution of the
electron density and its topology as a function of the reaction
coordinate has been elucidated in detail. The principal result is
a direct mechanism instead of the oft-quoted shuttle
mechanism of the peptide bond formation inside the ribosome
(Gindulyte et al., 2006; Massa et al., 2010). In this mechanism,
the amine hydrogen atom breaks away and is transferred
directly to the accepting oxygen atom that simultaneously
releases its attached amino acid to form the new peptide bond
with the growing peptide instead of being passed to the distal
oxygen which in turns passes its hydrogen atom to the active
oxygen atom as in the shuttle mechanism (Fig. 3).
Very recently, a novel integration of chemical graph theory
and QTAIM has been proposed (Matta, 2014; Sumar et al.,
2014). Matta (2014) has demonstrated that LIs and DIs
obtained from QTAIM (Bader, 1990) and organized in matrix
format constitute a molecular fingerprinting tool that can be
used in the predictive modeling of physicochemical properties
of molecules in the ground and excited states. The LI counts
the number of electrons that are localized within a given
atomic basin () of an atom in a molecule while the DI counts
the number of electrons that are shared between two different
basins (i and j). The newly defined matrix, termed the
localization–delocalization matrix (or the -matrix, or LDM)
lists the complete set of LIs [(i)] along the diagonal and the
complete set of the DIs (divided by two), (i, j)/2, i 6¼ j, as
the off-diagonal element. The LDMs are compact and efficient
numerical representations of the electronic structure of
molecules introduced and used as a predictive tool. It has been
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Figure 2
Comparison of total CPU times for converging single-point HF/STO-3G
full molecule and KEM calculations on the same processor. Reproduced
from the paper by Huang et al. (2014) with permission of the copyright
owner Elsevier 2014.
shown that Frobenius distances between matrix representa-
tions of the members of a series of molecules measures their
molecular dissimilarities. The LDM is defined (Matta, 2014) as
 
ð1Þ ð1;2Þ=2    ð1;nÞ=2






























where the sum of any column or row yields the corresponding
atomic population, as






The total molecular electron population is then given by the
sum of the column or row sums and can be expressed as the




























¼ N  trðÞ ¼ N  Nloc:
ð6Þ
The LDM contains information on electron localization and
delocalization, atomic charges [q() = Z  N(), where Z
is the atomic number], and interatomic distances because the
DIs decay systematically with internuclear separation. The
predictive value of the LDI matrices, when mathematically
manipulated with the tools developed within chemical graph
theory (Dimitriev, 2007; Hall & Klier, 1976; Janežič et al., 2007;
Todeschini & Consonni, 2009), is shown to quantify molecular
similarity in hydrocarbons, and provide predictive statistical
models for log P of the hydrocarbons (r2 = 0.994, n = 4) and for
the pKa values of substituted acetic acids (r
2 = 0.979, n = 7)
(Matta, 2014). More recently, the LDMs have been shown to
model the pKa values of a series of p-substituted benzoic acids
(r2 = 0.986, n = 14) and their UV max values (r
2 = 0.972, n = 8)
(Sumar et al., 2014). A discrepancy between the value for the
pKa = 6.03 of p-dimethylaminobenzoic acid (p-DMABA)
obtained from the CRC Handbook of Chemistry and Physics
(Lide, 2006, 2007) and that obtained from the -matrix-based
statistical model uncovered the incorrectness of the entry in
the CRC Handbook, which should be corrected to 5.03 in
agreement with the primary literature (Jover et al., 2008), the
value predicted from the -matrix-based model (Sumar et al.,
2014).
The LDM is not directly obtainable from experiment
(because the LIs and DIs necessitate the full density matrix for
their calculation), nevertheless, this matrix approach is based
on the partitioning of space based on the topology of the
electron density into non-overlapping atoms. Furthermore, the
concepts and the mathematical and numerical processing of
these matrices can readily be extended to experimentally
observable quantities cast in similar matrix formats. Examples
of such matrices include (but are not limited to) the bond
critical point (BCP) matrix termed the electron-density-
weighted connectivity matrix (Massa, 2014), the nuclear–
nuclear repulsion matrix, classical atom–atom electrostatic
repulsion or attraction matrix, etc.
The EDWCM consists of a listing, in a matrix format, of the
electron density at the BCP for every pair of bonded atoms in
a molecule, and hence, the EDWCM is derivable from both
experiment and theory. As in the case of the LDM, the
EDWCM is symmetric, but unlike the former, all the matrix
elements of pairs on non-bonded matrix elements are exactly
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Figure 3
(a) Model of the transition state where the arrow represents the eigenvector of the imaginary frequency (	im = 1084.1 i cm
3) indicating the transfer of H
from the amine N to O3 [the atom labeled ‘O’ in (a)] of the P-site ribose sugar. The O2 hydroxyl group of the P-site tRNA (O24—H43) forms a stable
hydrogen bond to the ester carbonyl group of the tRNA at the A-site (O4) (dashed line). (b) Molecular graph of the transition state: the large dark
spheres are located at the nuclear critical points of C atoms, the large red sphere those of the O nuclei, the blue spheres are N nuclei, and the large light-
gray spheres indicate the position of the H nuclear critical points. The lines of maximum electron density linking the nuclei are the bond paths and the
small red dots are the BCPs. The yellow dots are the ring critical points. BL indicates bond length.
(3)
zero since the BCP is non-existent. Fig. 4 depicts the molecular
graph of a water hydrogen-bonded dimer calculated at the
MP2/6-311+G(2d,2p) level of theory along with the atomic
numbering scheme and the values of the electron density at






O1 O2 H3 H4 H5 H6
O1 0 0 0:371 0:361 0 0
O2 0 0 0 0:023 0:368 0:368
H3 0:371 0 0 0 0 0
H4 0:361 0:023 0 0 0 0
H5 0 0:368 0 0 0 0
H6 0 0:368 0 0 0 0
; ð7Þ
represents an EDWCM of this water dimer given the atom







O1 O2 H3 H4 H5 H6
O1 8:615 0:027 0:310 0:256 0:000 0:000
O2 0:027 8:523 0:001 0:033 0:295 0:295
H3 0:310 0:001 0:116 0:003 0:000 0:000
H4 0:256 0:033 0:003 0:085 0:001 0:001
H5 0:000 0:295 0:000 0:001 0:105 0:004
H6 0:000 0:295 0:000 0:001 0:004 0:105
; ð8Þ
where the sums of the columns (or rows) yield: N(O1) = 9.208,
q(O1) = 1.208; N(O2) = 9.174, q(O2) = 1.174; N(H3) =
0.430, q(H3) = +0.570; N(H4) = 0.379, q(H4) = +0.621; N(H5)
= N(H6) = 0.405, q(H5) = q(H6) = +0.595 (where charges are
expressed in atomic units). The sum of all electron populations
is 20.001, the departure from the integer number of 20 elec-
trons reflecting the overall precision of the numerical inte-
gration over the QTAIM atomic basins.
10. Conclusion and outlook
It is clearly beneficial to combine methodology of both protein
and small-molecule crystallography for contributing answers
to research in medical chemistry. Database studies with
transferable pseudoatoms can fill in many gaps inaccessible by
classical CD research, and they allow computation of prop-
erties for macromolecular systems where quantum chemical
ab initio treatment becomes unfeasible; in refinement asphe-
rical scattering factors already help to increase the accuracy of
selected macromolecular structures. As an alternative to
property computation based on electron density, theoretical
approaches based on the wavefunction and coordinates from
XRD can provide a wealth of further properties and
descriptors. Despite impressive progress a lot of work remains
to be done; the key will be to combine different aspects where
progress has been noticeable. To shed light on drug–receptor
interactions it would be optimal to carry out a high-resolution
diffraction experiment at very low temperatures (e.g. on a
drug–receptor complex) making use of synchrotron radiation
and the latest detector technology, to refine a structure with
aspherical scattering factors (while evoking restraints that still
need to be developed), to find a way to successfully handle
disorder and to ultimately evaluate intermolecular interac-
tions (of different conformers) in a quantitative manner. In
other words, only when we are able to obtain the best possible
structures can we expect that intermolecular interaction
energies between macromolecules and drug molecules to be
meaningful. This is also true for theoretical approaches that
start from crystallographic structures to obtain energies such
as KEM. If such results can be achieved, we think they will be
able to provide real guidance for rational drug design.
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Dittrich, B., Flaig, R., Koritsánszky, T., Krane, H.-G., Morgenroth, W.
& Luger, P. (2000). Chem. Eur. J. 6, 2582–2589.
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